Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma
Zanubrutinib vs. acalabrutinib in B-cell malignancies: An adverse event-based economic analysis
Zanubrutinib (zanu) versus acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based economic analysis
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
Can We Speak to GPT to Inform Health Technology Assessments?

Unraveling Modeling Challenges in the Economic Evaluations of Gene Therapies: A Global Review

From Submission to Reimbursement: Navigating the COVID-19 Ripple Effect on Therapy Access in Canada

Methodological Insights on Indirect Treatment Comparisons for Ulcerative Colitis Therapies in NICE Submissions

Unleashing the Power of Social Media Listening: A Promising Tool for Patient-Focused Research

Q-TWiST Analysis Is Back in the Game in Oncology Clinical Trial Analysis: A Recent Trend
